Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Research Progress of Direct Thrombin Inhibitors

Author(s): Zhi-Gang Sun, Yang-Liu, Jin-Mai Zhang, Shi-Chang Cui, Zhi-Gang Zhang* and Hai-Liang Zhu*

Volume 20, Issue 16, 2020

Page: [1574 - 1585] Pages: 12

DOI: 10.2174/1389557519666191015201125

Price: $65

Abstract

Blood coagulation is the process of changing the blood from the flowing state to the gel state. It is an important part of the hemostatic function. Coagulation is a process by which a series of coagulation factors are sequentially activated, and finally thrombin is formed to form fibrin clot. Direct thrombin inhibitors are important anticoagulant drug. These drugs can selectively bind to the active site of thrombin, inhibit thrombin activity, have strong action and high specificity, and have important significance in the clinical treatment of thrombus diseases. Some of them come from natural products of animals or plants, and many of them have been applied in the clinic. The other part is derived from the design, synthesis and activity studies of small molecule inhibitors. This review discusses the progress of direct thrombin inhibitors in recent years.

Keywords: Thrombin inhibitor, natural product, blood coagulation, dabigatran, pyridine, benzofuran.

« Previous Next »
Graphical Abstract

[1]
Roth, G.A.; Johnson, C.; Abajobir, A.; Abd-Allah, F.; Abera, S.F.; Abyu, G.; Ahmed, M.; Aksut, B.; Alam, T.; Alam, K.; Alla, F.; Alvis-Guzman, N.; Amrock, S.; Ansari, H.; Ärnlöv, J.; Asayesh, H.; Atey, T.M.; Avila-Burgos, L.; Awasthi, A.; Banerjee, A.; Barac, A.; Bärnighausen, T.; Barregard, L.; Bedi, N.; Belay Ketema, E.; Bennett, D.; Berhe, G.; Bhutta, Z.; Bitew, S.; Carapetis, J.; Carrero, J.J.; Malta, D.C.; Castañeda-Orjuela, C.A.; Castillo-Rivas, J.; Catalá-López, F.; Choi, J.Y.; Christensen, H.; Cirillo, M.; Cooper, L., Jr; Criqui, M.; Cundiff, D.; Damasceno, A.; Dandona, L.; Dandona, R.; Davletov, K.; Dharmaratne, S.; Dorairaj, P.; Dubey, M.; Ehrenkranz, R.; El Sayed Zaki, M.; Faraon, E.J.A.; Esteghamati, A.; Farid, T.; Farvid, M.; Feigin, V.; Ding, E.L.; Fowkes, G.; Gebrehiwot, T.; Gillum, R.; Gold, A.; Gona, P.; Gupta, R.; Habtewold, T.D.; Hafezi-Nejad, N.; Hailu, T.; Hailu, G.B.; Hankey, G.; Hassen, H.Y.; Abate, K.H.; Havmoeller, R.; Hay, S.I.; Horino, M.; Hotez, P.J.; Jacobsen, K.; James, S.; Javanbakht, M.; Jeemon, P.; John, D.; Jonas, J.; Kalkonde, Y.; Karimkhani, C.; Kasaeian, A.; Khader, Y.; Khan, A.; Khang, Y.H.; Khera, S.; Khoja, A.T.; Khubchandani, J.; Kim, D.; Kolte, D.; Kosen, S.; Krohn, K.J.; Kumar, G.A.; Kwan, G.F.; Lal, D.K.; Larsson, A.; Linn, S.; Lopez, A.; Lotufo, P.A.; El Razek, H.M.A.; Malekzadeh, R.; Mazidi, M.; Meier, T.; Meles, K.G.; Mensah, G.; Meretoja, A.; Mezgebe, H.; Miller, T.; Mirrakhimov, E.; Mohammed, S.; Moran, A.E.; Musa, K.I.; Narula, J.; Neal, B.; Ngalesoni, F.; Nguyen, G.; Obermeyer, C.M.; Owolabi, M.; Patton, G.; Pedro, J.; Qato, D.; Qorbani, M.; Rahimi, K.; Rai, R.K.; Rawaf, S.; Ribeiro, A.; Safiri, S.; Salomon, J.A.; Santos, I.; Santric Milicevic, M.; Sartorius, B.; Schutte, A.; Sepanlou, S.; Shaikh, M.A.; Shin, M.J.; Shishehbor, M.; Shore, H.; Silva, D.A.S.; Sobngwi, E.; Stranges, S.; Swaminathan, S.; Tabarés-Seisdedos, R.; Tadele Atnafu, N.; Tesfay, F.; Thakur, J.S.; Thrift, A.; Topor-Madry, R.; Truelsen, T.; Tyrovolas, S.; Ukwaja, K.N.; Uthman, O.; Vasankari, T.; Vlassov, V.; Vollset, S.E.; Wakayo, T.; Watkins, D.; Weintraub, R.; Werdecker, A.; Westerman, R.; Wiysonge, C.S.; Wolfe, C.; Workicho, A.; Xu, G.; Yano, Y.; Yip, P.; Yonemoto, N.; Younis, M.; Yu, C.; Vos, T.; Naghavi, M.; Murray, C. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol., 2017, 70(1), 1-25.
[http://dx.doi.org/10.1016/j.jacc.2017.04.052] [PMID: 28527533]
[2]
Coutinho, J.M.; Zuurbier, S.M.; Aramideh, M.; Stam, J. The incidence of cerebral venous thrombosis: A cross-sectional study. Stroke, 2012, 43(12), 3373-3377.
[http://dx.doi.org/10.1161/STROKEAHA.112.671453] [PMID: 22996960]
[3]
DeVon, H.A.; Ryan, C.J.; Ochs, A.L.; Shapiro, M. Symptoms across the continuum of acute coronary syndromes: Differences between women and men. Am. J. Crit. Care, 2008, 17(1), 14-24.
[PMID: 18158385]
[4]
Alsén, P.; Brink, E.; Brändström, Y.; Karlson, B.W.; Persson, L.O. Fatigue after myocardial infarction: relationships with indices of emotional distress, and sociodemographic and clinical variables. Int. J. Nurs. Pract., 2010, 16(4), 326-334.
[http://dx.doi.org/10.1111/j.1440-172X.2010.01848.x] [PMID: 20649663]
[5]
Frazier, L.; Yu, E.; Sanner, J.; Liu, F.; Udtha, M.; Cron, S.; Coulter, S.; Bogaev, R.C. Gender differences in self-reported symptoms of depression among patients with acute coronary syndrome. Nurs. Res. Pract., 2012.2012109251
[http://dx.doi.org/10.1155/2012/109251] [PMID: 22567222]
[6]
Royle, N.J.; Irwin, D.M.; Koschinsky, M.L.; MacGillivray, R.T.; Hamerton, J.L. Human genes encoding prothrombin and ceruloplasmin map to 11p11-q12 and 3q21-24, respectively. Somat. Cell Mol. Genet., 1987, 13(3), 285-292.
[http://dx.doi.org/10.1007/BF01535211] [PMID: 3474786]
[7]
Davie, E.W.; Kulman, J.D. An overview of the structure and function of thrombin. Semin. Thromb. Hemost., 2006, 32, 3-15.
[http://dx.doi.org/10.1055/s-2006-939550]
[8]
Nar, H. The role of structural information in the discovery of direct thrombin and factor Xa inhibitors. Trends Pharmacol. Sci., 2012, 33(5), 279-288.
[http://dx.doi.org/10.1016/j.tips.2012.03.004] [PMID: 22503439]
[9]
Hirsh, J.; O’Donnell, M.; Weitz, J.I. New anticoagulants. Blood, 2005, 105(2), 453-463.
[http://dx.doi.org/10.1182/blood-2003-12-4195] [PMID: 15191946]
[10]
Mao, S.J.; Yates, M.T.; Owen, T.J.; Krstenansky, J.L. Interaction of hirudin with thrombin: Identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochemistry, 1988, 27(21), 8170-8173.
[http://dx.doi.org/10.1021/bi00421a027] [PMID: 3233202]
[11]
Seybert, A.L.; Coons, J.C.; Zerumsky, K. Treatment of heparin-induced thrombocytopenia: Is there a role for bivalirudin? Pharmacotherapy, 2006, 26(2), 229-241.
[http://dx.doi.org/10.1592/phco.26.2.229] [PMID: 16466327]
[12]
O’Dell, K.M.; Igawa, D.; Hsin, J. New oral anticoagulants for atrial fibrillation: A review of clinical trials. Clin. Ther., 2012, 34(4), 894-901.
[http://dx.doi.org/10.1016/j.clinthera.2012.01.019] [PMID: 22417716]
[13]
Di Nisio, M.; Middeldorp, S.; Büller, H.R. Direct thrombin inhibitors. N. Engl. J. Med., 2005, 353(10), 1028-1040.
[http://dx.doi.org/10.1056/NEJMra044440] [PMID: 16148288]
[14]
Graetz, T.J.; Tellor, B.R.; Smith, J.R.; Avidan, M.S. Desirudin: A review of the pharmacology and clinical application for the prevention of deep vein thrombosis. Expert Rev. Cardiovasc. Ther., 2011, 9(9), 1101-1109.
[http://dx.doi.org/10.1586/erc.11.131] [PMID: 21932952]
[15]
Baker, D.D.; Chu, M.; Oza, U.; Rajgarhia, V. The value of natural products to future pharmaceutical discovery. Nat. Prod. Rep., 2007, 24(6), 1225-1244.
[http://dx.doi.org/10.1039/b602241n] [PMID: 18033577]
[16]
Cragg, G.M.; Newman, D.J. Natural products: A continuing source of novel drug leads. Biochimica et Biophysica Acta (BBA) -. General Subjects, 2013, 1830(6), 3670-3695.
[http://dx.doi.org/10.1016/j.bbagen.2013.02.008]
[17]
Mishra, B.B.; Tiwari, V.K. Natural products: An evolving role in future drug discovery. Eur. J. Med. Chem., 2011, 46(10), 4769-4807.
[http://dx.doi.org/10.1016/j.ejmech.2011.07.057] [PMID: 21889825]
[18]
Liu, L.; Ma, H.; Yang, N.; Tang, Y.; Guo, J.; Tao, W.; Duan, J. A series of natural flavonoids as thrombin inhibitors: Structureactivity relationships. Thromb. Res., 2010, 126(5), e365-e378.
[http://dx.doi.org/10.1016/j.thromres.2010.08.006] [PMID: 20828797]
[19]
Shi, Z.H.; Li, N.G.; Tang, Y.P.; Wei-Li, Y.P.; Lian-Yin, Y.P.; Yang, J.P.; Hao-Tang, Y.P.; Duan, J.A. Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors. Eur. J. Med. Chem., 2012, 54(11), 210-222.
[http://dx.doi.org/10.1016/j.ejmech.2012.04.044] [PMID: 22647223]
[20]
Li, N-G.; Song, S-L.; Shen, M-Z.; Tang, Y-P.; Shi, Z-H.; Tang, H.; Shi, Q-P.; Fu, Y-F.; Duan, J-A. Mannich bases of scutellarein as thrombin-inhibitors: Design, synthesis, biological activity and solubility. Bioorg. Med. Chem., 2012, 20(24), 6919-6923.
[http://dx.doi.org/10.1016/j.bmc.2012.10.015] [PMID: 23131413]
[21]
Rodrigues, C.F.B.; Gaeta, H.H.; Belchor, M.N.; Ferreira, M.J.P.; Pinho, M.V.T. Toyama, Dde.O.; Toyama, M.H. Evaluation of potential thrombin inhibitors from the white mangrove (Laguncularia racemosa (L.) CF Gaertn.). Mar. Drugs, 2015, 13(7), 4505-4519.
[http://dx.doi.org/10.3390/md13074505] [PMID: 26197325]
[22]
Lu, J.; Song, H-P.; Li, P.; Zhou, P.; Dong, X.; Chen, J. Screening of direct thrombin inhibitors from Radix Salviae Miltiorrhizae by a peak fractionation approach. J. Pharm. Biomed. Anal., 2015, 109, 85-90.
[http://dx.doi.org/10.1016/j.jpba.2015.02.020] [PMID: 25819728]
[23]
Wang, X.; Zhang, Y.; Yang, Y.; Wu, X.; Fan, H.; Qiao, Y. Identification of berberine as a direct thrombin inhibitor from traditional Chinese medicine through structural, functional and binding studies. Sci. Rep., 2017, 7, 44040.
[http://dx.doi.org/10.1038/srep44040] [PMID: 28276481]
[24]
Waxman, L.; Smith, D.E.; Arcuri, K.E.; Vlasuk, G.P. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science, 1990, 248(4955), 593-596.
[http://dx.doi.org/10.1126/science.2333510] [PMID: 2333510]
[25]
Iyer, J.K.; Koh, C.Y.; Kazimirova, M.; Roller, L.; Jobichen, C.; Swaminathan, K.; Mizuguchi, J.; Iwanaga, S.; Nuttall, P.A.; Chan, M.Y.; Kini, R.M. Avathrin: A novel thrombin inhibitor derived from a multicopy precursor in the salivary glands of the ixodid tick, Amblyomma variegatum. FASEB J., 2017, 31(7), 2981-2995.
[http://dx.doi.org/10.1096/fj.201601216R] [PMID: 28363953]
[26]
Gardell, S.J.; Ramjit, D.R.; Stabilito, I.I.; Fujita, T.; Lynch, J.J.; Cuca, G.C.; Jain, D.; Wang, S.P.; Tung, J.S.; Mark, G.E. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation, 1991, 84(1), 244-253.
[http://dx.doi.org/10.1161/01.CIR.84.1.244] [PMID: 1905593]
[27]
Cappello, M.; Vlasuk, G.P.; Bergum, P.W.; Huang, S.; Hotez, P.J. Ancylostoma caninum anticoagulant peptide: A hookworm-derived inhibitor of human coagulation factor Xa. Proc. Natl. Acad. Sci. USA, 1995, 92(13), 6152-6156.
[http://dx.doi.org/10.1073/pnas.92.13.6152] [PMID: 7597095]
[28]
Sawyer, R.T. Thrombolytics and anti-coagulants from leeches. Biotechnology (N. Y.), 1991, 9(6), 513-515, 518.
[PMID: 1367219]
[29]
Markwardt, F. Hirudin as an inhibitor of thrombin. Methods Enzymol., 1970, 19, 924-932.
[http://dx.doi.org/10.1016/0076-6879(70)19082-3]
[30]
Steiner, V.; Knecht, R.; Börnsen, K.O.; Gassmann, E.; Stone, S.R.; Raschdorf, F.; Schlaeppi, J.M.; Maschler, R. Primary structure and function of novel O-glycosylated hirudins from the leech Hirudinaria manillensis. Biochemistry, 1992, 31(8), 2294-2298.
[http://dx.doi.org/10.1021/bi00123a012] [PMID: 1540584]
[31]
Krstenansky, J.L.; Owen, T.J.; Yates, M.T.; Mao, S.J. The Cterminal binding domain of hirullin P18. Antithrombin activity and comparison to hirudin peptides. FEBS Lett., 1990, 262(2), 425-429.
[http://dx.doi.org/10.1016/0014-5793(90)81208-6] [PMID: 2401369]
[32]
Strube, K.H.; Kröger, B.; Bialojan, S.; Otte, M.; Dodt, J. Isolation, sequence analysis, and cloning of haemadin. An anticoagulant peptide from the Indian leech. J. Biol. Chem., 1993, 268(12), 8590-8595.
[PMID: 8473305]
[33]
Jablonka, W.; Kotsyfakis, M.; Mizurini, D.M.; Monteiro, R.Q.; Lukszo, J.; Drake, S.K.; Ribeiro, J.M.; Andersen, J.F. Identification and mechanistic analysis of a novel tick-derived inhibitor of thrombin. PLoS One, 2015, 10(8)e0133991
[http://dx.doi.org/10.1371/journal.pone.0133991] [PMID: 26244557]
[34]
Brahma, R.K.; Blanchet, G.; Kaur, S.; Manjunatha Kini, R.; Doley, R. Expression and characterization of haemathrins, madanin-like thrombin inhibitors, isolated from the salivary gland of tick Haemaphysalis bispinosa (Acari: Ixodidae). Thromb. Res., 2017, 152, 20-29.
[http://dx.doi.org/10.1016/j.thromres.2017.01.012] [PMID: 28213103]
[35]
Ibrahim, M.A.; Masoud, H.M.M. Thrombin inhibitor from the salivary gland of the camel tick Hyalomma dromedarii. Exp. Appl. Acarol., 2018, 74(1), 85-97.
[http://dx.doi.org/10.1007/s10493-017-0196-9] [PMID: 29255966]
[36]
Bohmann, F.; Mirceska, A.; Pfeilschifter, J.; Lindhoff-Last, E.; Steinmetz, H.; Foerch, C.; Pfeilschifter, W. No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. PLoS One, 2012, 7(7)e40804
[http://dx.doi.org/10.1371/journal.pone.0040804] [PMID: 22911709]
[37]
Kwon, I.; An, S.; Kim, J.; Yang, S-H.; Yoo, J.; Baek, J-H.; Nam, H.S.; Kim, Y.D.; Lee, H.S.; Choi, H-J.; Heo, J.H. Hemorrhagic transformation after large cerebral infarction in rats pretreated with dabigatran or warfarin. Stroke, 2017, 48(10), 2865-2871.
[http://dx.doi.org/10.1161/STROKEAHA.117.017751] [PMID: 28904233]
[38]
Lauer, A.; Cianchetti, F.A.; Van Cott, E.M.; Schlunk, F.; Schulz, E.; Pfeilschifter, W.; Steinmetz, H.; Schaffer, C.B.; Lo, E.H.; Foerch, C. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation, 2011, 124(15), 1654-1662.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.035972] [PMID: 21911784]
[39]
Choi, H.J.; Kim, N.E.; Kim, J.; An, S.; Yang, S.H.; Ha, J.; Cho, S.; Kwon, I.; Kim, Y.D.; Nam, H.S.; Heo, J.H. Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization. Thromb. Res., 2018, 167, 165-171.
[http://dx.doi.org/10.1016/j.thromres.2018.04.019] [PMID: 29735342]
[40]
Li, C.L.; Dong, M.H.; Ren, Y.J.; Li, L.H. Design, synthesis, biological evaluation and molecular docking of novel dabigatran derivatives as potential thrombin inhibitors. RSC Advances, 2015, 5(30), 23737-23748.
[http://dx.doi.org/10.1039/C5RA01828E]
[41]
Li, M.; Ren, Y. Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-1H-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors. Arch. Pharm. (Weinheim), 2015, 348(5), 353-365.
[http://dx.doi.org/10.1002/ardp.201400463] [PMID: 25824648]
[42]
Li, M.L.; Ren, Y.J.; Dong, M.H.; Ren, W.X. Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors. Eur. J. Med. Chem., 2015, 96, 122-138.
[http://dx.doi.org/10.1016/j.ejmech.2015.04.012] [PMID: 25874337]
[43]
Chen, H.; Ren, Y. Design, synthesis, and anti-thrombotic evaluation of some novel fluorinated thrombin inhibitor derivatives. Arch. Pharm. (Weinheim), 2015, 348(6), 408-420.
[http://dx.doi.org/10.1002/ardp.201400460] [PMID: 25881141]
[44]
Chen, H.F.; Dong, M.H.; Ren, Y.J.; Wang, F. Design, synthesis, biological evaluation and molecular docking studies of dabigatran analogs as potential thrombin inhibitors. J. Indian Chem. Soc., 2016, 13(2), 347-357.
[http://dx.doi.org/10.1007/s13738-015-0743-4]
[45]
Dong, M.H.; Chen, H.F.; Ren, Y.J.; Shao, F.M. Molecular modeling studies, synthesis and biological evaluation of dabigatran analogues as thrombin inhibitors. Bioorg. Med. Chem., 2016, 24(2), 73-84.
[http://dx.doi.org/10.1016/j.bmc.2015.11.025] [PMID: 26690913]
[46]
Ren, W.; Ren, Y.; Wang, S. Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives. Eur. J. Med. Chem., 2016, 120, 148-159.
[http://dx.doi.org/10.1016/j.ejmech.2016.05.020] [PMID: 27187866]
[47]
Yang, H.; Liu, Q.; Gao, X.; Ren, Y.; Gao, Y. Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation. Eur. J. Med. Chem., 2017, 126, 799-809.
[http://dx.doi.org/10.1016/j.ejmech.2016.12.015] [PMID: 27951488]
[48]
Yang, X.Z.; Yang, W.H.; Xu, Y.G.; Diao, X.J.; He, G.W.; Gong, G.Q. Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity. Eur. J. Med. Chem., 2012, 57(4), 21-28.
[http://dx.doi.org/10.1016/j.ejmech.2012.09.016] [PMID: 23043765]
[49]
Yang, X.Z.; Diao, X.J.; Yang, W.H.; Li, F.; He, G.W.; Gong, G.Q.; Xu, Y.G. Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate. Bioorg. Med. Chem. Lett., 2013, 23(7), 2089-2092.
[http://dx.doi.org/10.1016/j.bmcl.2013.01.126] [PMID: 23466230]
[50]
Wang, S.; Dai, P.; Xu, Y.; Chen, Q.; Zhu, Q.; Gong, G. Design, synthesis, and biological evaluation of dabigatran etexilate mimics, a novel class of thrombin inhibitors. Arch. Pharm. (Weinheim), 2015, 348(8), 595-605.
[http://dx.doi.org/10.1002/ardp.201500101] [PMID: 26120827]
[51]
Chen, D.; Wang, S.; Diao, X.; Zhu, Q.; Shen, H.; Han, X.; Wang, Y.; Gong, G.; Xu, Y. Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors. Bioorg. Med. Chem., 2015, 23(23), 7405-7416.
[http://dx.doi.org/10.1016/j.bmc.2015.10.036] [PMID: 26537784]
[52]
Saal, W.V.D.; Kucznierz, R.; Leinert, H.; Engh, R.A. derivatives of 4-amino-pyridine as selective thrombin inhibitors. Bioorg. Med. Chem. Lett., 1997, 7(10), 1283-1288.
[http://dx.doi.org/10.1016/S0960-894X(97)00210-2]
[53]
Burgey, C.S.; Robinson, K.A.; Lyle, T.A.; Nantermet, P.G.; Selnick, H.G.; Isaacs, R.C.; Lewis, S.D.; Lucas, B.J.; Krueger, J.A.; Singh, R.; Miller-Stein, C.; White, R.B.; Wong, B.; Lyle, E.A.; Stranieri, M.T.; Cook, J.J.; McMasters, D.R.; Pellicore, J.M.; Pal, S.; Wallace, A.A.; Clayton, F.C.; Bohn, D.; Welsh, D.C.; Lynch, J.J., Jr; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S.J.; Shafer, J.A.; Vacca, J.P. Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 Nbenzylamides. Bioorg. Med. Chem. Lett., 2003, 13(7), 1353-1357.
[http://dx.doi.org/10.1016/S0960-894X(03)00099-4] [PMID: 12657281]
[54]
Burgey, C.S.; Robinson, K.A.; Lyle, T.A.; Sanderson, P.E.; Lewis, S.D.; Lucas, B.J.; Krueger, J.A.; Singh, R.; Miller-Stein, C.; White, R.B.; Wong, B.; Lyle, E.A.; Williams, P.D.; Coburn, C.A.; Dorsey, B.D.; Barrow, J.C.; Stranieri, M.T.; Holahan, M.A.; Sitko, G.R.; Cook, J.J.; McMasters, D.R.; McDonough, C.M.; Sanders, W.M.; Wallace, A.A.; Clayton, F.C.; Bohn, D.; Leonard, Y.M.; Detwiler, T.J., Jr; Lynch, J.J., Jr; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S.J.; Shafer, J.A.; Vacca, J.P. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. J. Med. Chem., 2003, 46(4), 461-473.
[http://dx.doi.org/10.1021/jm020311f] [PMID: 12570369]
[55]
Nantermet, P.G.; Burgey, C.S.; Robinson, K.A.; Pellicore, J.M.; Newton, C.L.; Deng, J.Z.; Selnick, H.G.; Lewis, S.D.; Lucas, B.J.; Krueger, J.A.; Miller-Stein, C.; White, R.B.; Wong, B.; McMasters, D.R.; Wallace, A.A.; Lynch, J.J., Jr; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S.J.; Shafer, J.A.; Vacca, J.P.; Lyle, T.A. P2 pyridine N-oxide thrombin inhibitors: A novel peptidomimetic scaffold. Bioorg. Med. Chem. Lett., 2005, 15(11), 2771-2775.
[http://dx.doi.org/10.1016/j.bmcl.2005.03.110] [PMID: 15911253]
[56]
Blomberg, D.; Fex, T.; Xue, Y.; Brickmann, K.; Kihlberg, J. Design, synthesis and biological evaluation of thrombin inhibitors based on a pyridine scaffold. Org. Biomol. Chem., 2007, 5(16), 2599-2605.
[http://dx.doi.org/10.1039/b705344d] [PMID: 18019535]
[57]
Lee, L.; Kreutter, K.D.; Pan, W.; Crysler, C.; Spurlino, J.; Player, M.R.; Tomczuk, B.; Lu, T. 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(22), 6266-6269.
[http://dx.doi.org/10.1016/j.bmcl.2007.09.013] [PMID: 17889527]
[58]
de Candia, M.; Fiorella, F.; Lopopolo, G.; Carotti, A.; Romano, M.R.; Lograno, M.D.; Martel, S.; Carrupt, P.A.; Belviso, B.D.; Caliandro, R.; Altomare, C. Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity. J. Med. Chem., 2013, 56(21), 8696-8711.
[http://dx.doi.org/10.1021/jm401169a] [PMID: 24102612]
[59]
Aoyama, H.; Ijuin, R.; Kato, J.Y.; Urushiyama, S.; Tetsuhashi, M.; Hashimoto, Y.; Yokomatsu, T. Discovery of non-competitive thrombin inhibitor derived from competitive tryptase inhibitor skeleton: Shift in molecular recognition resulted from skeletal conversion of carboxylate into phosphonate. Bioorg. Med. Chem. Lett., 2015, 25(17), 3676-3680.
[http://dx.doi.org/10.1016/j.bmcl.2015.06.039] [PMID: 26122211]
[60]
Sidhu, P.S.; Liang, A.; Mehta, A.Y.; Abdel Aziz, M.H.; Zhou, Q.; Desai, U.R. Rational design of potent, small, synthetic allosteric inhibitors of thrombin. J. Med. Chem., 2011, 54(15), 5522-5531.
[http://dx.doi.org/10.1021/jm2005767] [PMID: 21714536]
[61]
Sidhu, P.S.; Abdel Aziz, M.H.; Sarkar, A.; Mehta, A.Y.; Zhou, Q.; Desai, U.R. Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition. J. Med. Chem., 2013, 56(12), 5059-5070.
[http://dx.doi.org/10.1021/jm400369q] [PMID: 23718540]
[62]
Afosah, D.K.; Verespy, S., III; Al-Horani, R.A.; Boothello, R.S.; Karuturi, R.; Desai, U.R. A small group of sulfated benzofurans induces steady-state submaximal inhibition of thrombin. Bioorg. Med. Chem. Lett., 2018, 28(6), 1101-1105.
[http://dx.doi.org/10.1016/j.bmcl.2018.01.069] [PMID: 29459207]
[63]
Salimbeni, A.; Paleari, F.; Canevotti, R.; Criscuoli, M.; Criscuoli, M.; Lippi, A.; Angiolini, M.; Belvisi, L.; Scolastico, C.; Colombo, L. Design and synthesis of conformationally constrained arginal thrombin inhibitors. Bioorg. Med. Chem. Lett., 1997, 7(17), 2205-2210.
[http://dx.doi.org/10.1016/S0960-894X(97)00403-4]
[64]
Zega, A.; Mlinsek, G.; Solmajer, T.; Trampus-Bakija, A.; Stegnar, M.; Urleb, U. Thrombin inhibitors built on an azaphenylalanine scaffold. Bioorg. Med. Chem. Lett., 2004, 14(6), 1563-1567.
[http://dx.doi.org/10.1016/j.bmcl.2003.12.083] [PMID: 15006404]
[65]
Isaacs, R.C.A.; Newton, C.L.; Cutrona, K.J.; Mercer, S.P.; Payne, L.S.; Stauffer, K.J.; Williams, P.D.; Cook, J.J.; Krueger, J.A.; Lewis, S.D.; Lucas, B.J.; Lyle, E.A.; Lynch, J.J.; McMasters, D.R.; Naylor-Olsen, A.M.; Michener, M.T.; Wallace, A.A. Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(5), 1536-1540.
[http://dx.doi.org/10.1016/j.bmcl.2010.12.105] [PMID: 21295467]
[66]
Blizzard, T.A.; Singh, S.; Patil, B.; Chidurala, N.; Komanduri, V.; Debnath, S.; Belyakov, S.; Crespo, A.; Struck, A.; Kurtz, M.; Wiltsie, J.; Shen, X.; Sonatore, L.; Arocho, M.; Lewis, D.; Ogletree, M.; Biftu, T. Heterocyclic core analogs of a direct thrombin inhibitor. Bioorg. Med. Chem. Lett., 2014, 24(4), 1111-1115.
[http://dx.doi.org/10.1016/j.bmcl.2014.01.002] [PMID: 24461292]
[67]
Verespy, S., III; Mehta, A.Y.; Afosah, D.; Al-Horani, R.A.; Desai, U.R. Allosteric partial inhibition of monomeric proteases. sulfated coumarins induce regulation, not just inhibition, of thrombin. Sci. Rep., 2016, 6, 24043.
[http://dx.doi.org/10.1038/srep24043] [PMID: 27053426]
[68]
Chen, D.; Shi, J.; Liu, J.; Zhang, X.; Deng, X.; Yang, Y.; Cui, S.; Zhu, Q.; Gong, G.; Xu, Y. Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors. Bioorg. Med. Chem., 2017, 25(2), 458-470.
[http://dx.doi.org/10.1016/j.bmc.2016.11.012] [PMID: 27884512]

Rights & Permissions Print Cite
Article Metrics
53
2
© 2024 Bentham Science Publishers | Privacy Policy